News

Allon Therapeutics selected by the Alzheimer's Disease Cooperative Study

VANCOUVER, April 26 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), announced today that its Alzheimer's clinical development program has been selected by the Alzheimer's Disease Cooperative Study (ADCS) in the United States to be included in its submission to re... Continue reading →

Allon Therapeutics to Present at Technology and Life Sciences Forum

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 21, 2005) - Allon Therapeutics Inc. (TSX VENTURE:NPC), The Neuro Protection Company(TM), will participate in the 2005 Fasken Martineau Technology and Life Sciences Forum April 27th. Gordon McCauley, President of Allon, will share information on th... Continue reading →

Allon Therapeutics compounds show potential to repair central nervous system cells after disease or injury

VANCOUVER, April 19 /CNW/ - Two proprietary compounds of Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), have the potential to become new treatments that contribute to development and repair of central nervous system cells damaged by neurodegenerative disease or injury, ... Continue reading →

Allon Therapeutics presents at European BioSquare partnering conference

VANCOUVER, April 14 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), is today presenting an update of the company's clinical development program and overall business strategy at Biosquare 2005, a life sciences partnering conference in Lyon, France. Gordon McCaule... Continue reading →

Allon reports 2004 audited operating results

VANCOUVER, April 12 /CNW/ - Allon Therapeutics Inc. (TSX-V: "NPC"), The Neuro Protection Company(TM), reported today its 2004 audited operating results. The Company met all of its publicly stated milestones in 2004 and subsequently has met all of its year-to-date 2005 milestones. Financials For... Continue reading →

← Older posts Newer posts →